Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 49–72 of 155
Unnatural Products raised $45 million to advance macrocyclic peptide therapeutics targeting intracellular protein interactions implicated in cardiometabolic, inflammatory, and age-related diseases. This technology addresses a critical gap in drug development by enabling selective modulation of previously inaccessible cellular pathways.
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Natural killer cells from older adults show reduced capacity to eliminate senescent and cancer cells due to impaired granule release and cytotoxic machinery, not recognition defects. Targeting elevated Cdc42 protein and restoring microtubular organization represents a potential intervention to restore NK cell function with age.
Blocking growth hormone signaling specifically in adipose tissue reduces neuroinflammation, preserves synaptic integrity, and improves cognitive performance across multiple domains in aged mice. This identifies peripheral adipose tissue as an unexpected regulator of brain aging, suggesting a therapeutic target for age-related cognitive decline.
Cellular senescence in ectopic endometrial tissue drives aggressive endometriosis through a PAK4/AKT signaling loop that promotes macrophage-mediated immune remodeling. Stigmasterol, a plant-derived phytosterol, suppresses this pathway and reduces lesion invasiveness in preclinical models, suggesting a mechanism-based therapeutic approach to a senescence-driven disease subtype.
Researchers studying animals that recover from extreme stress—hibernating ground squirrels and aging dogs—are identifying reversible mechanisms of age-related disease that human datasets alone may never reveal. This approach reframes aging as a problem with existing biological solutions rather than inevitable decline.
Mesoblast acquired exclusive worldwide rights to a chimeric antigen receptor technology platform developed at Mayo Clinic to enhance its mesenchymal stromal cell therapeutic products. This expansion targets inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, lupus nephritis, and B-cell autoimmune conditions.
Sana Biotechnology and Mayo Clinic are advancing SC451, a cell therapy that replaces destroyed pancreatic islet cells in Type 1 diabetes by engineering them to evade immune attack, potentially eliminating the need for lifelong insulin management. Early data shows transplanted cells remaining functional for over a year without immunosuppression, establishing a proof-of-concept for broader tissue replacement applications.
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Longeveron secured a Chinese patent for mesenchymal stem cell potency assays, extending its intellectual property protection through 2041. This standardization of cell quality assessment is foundational for regulatory approval of cell-based therapies, particularly as the company advances laromestrocel in aging-related frailty and cardiac disease.
Serum extracellular vesicles carry distinct molecular signatures—small noncoding RNAs and mitochondrial proteins—that differentiate older adults with preserved mobility from those with age-related gait decline. These circulating vesicles appear to mediate brain-muscle communication and may serve as noninvasive biomarkers for identifying individuals at risk of functional decline.
Unnatural Products and Novartis have partnered to develop macrocyclic peptides—molecular structures between small molecules and biologics—targeting protein interactions implicated in cardiovascular disease and age-related conditions. This approach addresses a critical gap in drug development where conventional therapeutics cannot effectively engage disease-driving targets.
Nuritas is presenting PeptiStrong functional food prototypes containing AI-identified bioactive peptides from natural food sources, designed to support metabolic health, muscle maintenance, and stress regulation through familiar consumer formats like yogurt and beverages. The approach represents an effort to translate precision peptide science into accessible mainstream wellness products.
Mesoblast received FDA clearance to advance Ryoncil, a mesenchymal stromal cell therapy, into a registrational trial for Duchenne muscular dystrophy in children aged 5-9. The therapy targets the inflammatory cascade underlying DMD progression, with time-to-stand at 9 months as the primary efficacy endpoint.
XellSmart has secured IND clearance for a Phase I/II trial of iPSC-derived neuron progenitor cells targeting multiple system atrophy-Parkinsonian type, marking its fourth consecutive regulatory approval for CNS cell therapies. This represents clinical validation of allogeneic, off-the-shelf regenerative approaches for a rapidly progressive neurodegenerative disease with no disease-modifying treatments.
Rubedo's RLS-1496, a GPX4 modulator designed to target senescent cells, met primary safety endpoints in a Phase 1 trial and demonstrated dose-dependent clinical improvements in psoriasis, atopic dermatitis, and photoaged skin within four weeks. The compound showed reduced senescent cell burden, decreased inflammatory markers, and increased collagen expression with no serious adverse events.
Vesalic has identified a systemic metabolic dysfunction originating outside the brain that drives ALS pathology through circulating exosomes carrying toxic cargo to motor neurons. This reframes ALS as a systemic disease rather than a purely CNS disorder, redirecting therapeutic strategy away from decades of brain-focused approaches with limited success.
Cell therapy manufacturing capacity is becoming a critical bottleneck as the market expands toward $14 billion by 2035. A joint venture between Avaí Bio and Austrianova is scaling production of genetically modified cells engineered to elevate circulating alpha-Klotho, a protein associated with cellular resilience and healthspan.
Sana Biotechnology's hypoimmune islet cell transplants achieved one-year persistence and function in a Type 1 diabetes patient without systemic immunosuppression, validating a cell-engineering approach that modifies transplanted cells rather than suppressing the immune system. This durability milestone suggests scalable, off-the-shelf cell therapies may be feasible without the toxicity burden of traditional immunosuppression.
BioCardia's CardiAMP cell therapy for ischemic heart failure has received regulatory alignment from Japan's PMDA, with an estimated 20,000 eligible patients among Japan's 300,000 with reduced ejection fraction. The pathway forward requires demonstration of patient eligibility criteria and post-marketing surveillance protocols before commercial authorization.
PROTACs—molecules that selectively degrade disease-causing proteins via the cell's natural ubiquitin-proteasome system—represent a mechanistic departure from traditional inhibitor-based therapies. The market is forecast to expand significantly through 2034, driven by 90 protein-degradation leads in development and pipeline expansion across oncology, neurodegenerative, and inflammatory indications.
Mesoblast has received FDA clearance to conduct a registrational trial of Ryoncil, an allogeneic mesenchymal stem cell therapy, in pediatric Duchenne muscular dystrophy patients aged 5-9 years. The trial will assess whether the therapy's anti-inflammatory properties can preserve muscle function and slow disease progression in a population with limited treatment options.
Cellular retinoic acid-binding protein 1 (CRABP1) regulates thyroid aging through vitamin A metabolism and retinoic acid signaling. Dysfunction in this protein correlates with thyroid senescence, positioning CRABP1 as a potential biomarker and intervention target for age-related thyroid decline.
